SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genta, Inc. (GNTA)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1870 44 0 GNTA
Emcee:  John Nobrega Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1720Preclinical Results Show Genasense(TM) Synergizes with Campath(R) in Chronic Lymbob zagorin-6/4/2003
1719Genta to Present at Needham & Company Second Annual Biotechnology Conferencebob zagorin-6/4/2003
1718Aventis says Europeans to start Genasense trial PARIS, June 3 (Reuters) - Francbob zagorin-6/3/2003
1717Genasense(TM) Plus Taxotere(R) Reported Active in Patients with Hormone-Refractobob zagorin-6/3/2003
1716Genasense(TM) Combination With Chemotherapy Reported Useful in Newly Diagnosed Pbob zagorin-6/3/2003
1715Clinical Study Results Show Genasense(TM) May Delay Progression in Patients Withbob zagorin-6/2/2003
1714Good News Expected From Biotechs at Cancer Meeting Thursday May 29, 5:46 pm ET bob zagorin-5/29/2003
1713Good News Expected From Biotechs at Cancer Meeting Thursday May 29, 5:46 pm ET bob zagorin-5/29/2003
1712Genta Announces Promotion of Dr. Loretta M. Itri to President, Pharmaceutical Debob zagorin-5/27/2003
1711Clinical Activity of Genasense in Patients with Refractory Myeloma Highlighted ibob zagorin-5/27/2003
17109:48AM Genta upped to Outperform at Ryan Beck; target $13 (GNTA) 8.70 +0.24: Thebob zagorin-5/5/2003
1709strong buy reiterated from needham todaybob zagorin-5/2/2003
1708Genta Announces 1st Quarter 2003 Financial Results and Highlights Conference Calbob zagorin-5/1/2003
1707Genta Incorporated Announces Conference Call and Webcast to Discuss First Quartebob zagorin-4/27/2003
1706BCL2 VS Survivin: What's the difference? "ISIS 23722 targets survivinJohn William Anderson-4/21/2003
1705StayinFront: StayinFront to provide Genta with CRM solution for sales force and bob zagorin-4/15/2003
1704New Study Shows Biomarkers May Determine Responsiveness to Ganite(TM) In Non-Hodbob zagorin-4/10/2003
1703amen.bob zagorin-4/10/2003
1702About 6 million people worldwide die of cancer each year. About 300,000 people John William Anderson-4/9/2003
1701Single-Agent Activity of Genta's Lead Anticancer Compound, Genasense(TM), Rebob zagorin-4/9/2003
1700Preclinical Activity of Genasense(TM) Documented in Non-Small Cell Lung Cancer Bbob zagorin-4/8/2003
1699New Preclinical Data Demonstrate Optimized Treatment Schedules of Genasense(TM) bob zagorin-4/7/2003
1698Genta Completes FDA Submission of New Drug Application for Ganite(TM) (gallium nbob zagorin-4/1/2003
1697Genta CEO Provides Clinical, Regulatory, and Financial Update at Banc of Americabob zagorin-3/26/2003
1696Genta Incorporated to Present at Banc of America 2003 Healthcare Conference Bbob zagorin-3/19/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News